161 related articles for article (PubMed ID: 31302306)
1. Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases.
Axelrad JE; Bazarbashi A; Zhou J; Castañeda D; Gujral A; Sperling D; Glass J; Agrawal M; Hong S; Lawlor G; Hudesman D; Chang S; Shah S; Yajnik V; Ananthakrishnan A; Khalili H; Colombel JF; Itzkowitz S;
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):872-880.e1. PubMed ID: 31302306
[TBL] [Abstract][Full Text] [Related]
2. Effects of cancer treatment on inflammatory bowel disease remission and reactivation.
Axelrad JE; Fowler SA; Friedman S; Ananthakrishnan AN; Yajnik V
Clin Gastroenterol Hepatol; 2012 Sep; 10(9):1021-7.e1. PubMed ID: 22732273
[TBL] [Abstract][Full Text] [Related]
3. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.
Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH;
Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028
[TBL] [Abstract][Full Text] [Related]
5. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
[TBL] [Abstract][Full Text] [Related]
6. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
Molander P; Färkkilä M; Kemppainen H; Blomster T; Jussila A; Mustonen H; Sipponen T
Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
[TBL] [Abstract][Full Text] [Related]
8. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
Kennedy NA; Warner B; Johnston EL; Flanders L; Hendy P; Ding NS; Harris R; Fadra AS; Basquill C; Lamb CA; Cameron FL; Murray CD; Parkes M; Gooding I; Ahmad T; Gaya DR; Mann S; Lindsay JO; Gordon J; Satsangi J; Hart A; McCartney S; Irving P; ; Lees CW
Aliment Pharmacol Ther; 2016 Apr; 43(8):910-923. PubMed ID: 26892328
[TBL] [Abstract][Full Text] [Related]
9. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease.
Limketkai BN; Iheozor-Ejiofor Z; Gjuladin-Hellon T; Parian A; Matarese LE; Bracewell K; MacDonald JK; Gordon M; Mullin GE
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012839. PubMed ID: 30736095
[TBL] [Abstract][Full Text] [Related]
10. Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
de Lima-Karagiannis A; Zelinkova-Detkova Z; van der Woude CJ
Am J Gastroenterol; 2016 Sep; 111(9):1305-12. PubMed ID: 27349339
[TBL] [Abstract][Full Text] [Related]
12. Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study.
Olén O; Smedby KE; Erichsen R; Pedersen L; Halfvarson J; Hallqvist-Everhov Å; Bryder N; ; Askling J; Ekbom A; Sachs MC; Sørensen HT; Ludvigsson JF
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3132-3142. PubMed ID: 37061104
[TBL] [Abstract][Full Text] [Related]
13. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
15. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
[TBL] [Abstract][Full Text] [Related]
16. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India.
Sahu P; Vuyyuru SK; Kante B; Agarwal A; Sharma R; Das P; Panwar R; Jain S; Bopanna S; Makharia G; Kedia S; Ahuja V
Indian J Gastroenterol; 2020 Aug; 39(4):388-397. PubMed ID: 32880844
[TBL] [Abstract][Full Text] [Related]
17. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014.
Ludvigsson JF; Mahl M; Sachs MC; Björk J; Michaelsson K; Ekbom A; Askling J; Backman AS; Olén O
Am J Gastroenterol; 2019 Feb; 114(2):291-304. PubMed ID: 30730858
[TBL] [Abstract][Full Text] [Related]
18. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
